New allergy intervention strategies: Hitting the mucosal road

Clinical and Experimental Allergy

Volumn 37, Issue 4, 2007, Pages 473-475

  Wiedermann, U ^a   Mercenier, A ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; PHLEUM PRATENSE EXTRACT; PLANT EXTRACT; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ATOPIC DERMATITIS; BIFIDOBACTERIUM ANIMALIS; BRONCHUS HYPERREACTIVITY; CYTOKINE PRODUCTION; EDITORIAL; HOSPICE; HUMAN; IMMUNOTHERAPY; INTESTINE FLORA; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MUCOSA; NONHUMAN; NOSE MUCUS; PHLEUM PRATENSE; PRIORITY JOURNAL; SENSITIZATION; SNEEZING; T LYMPHOCYTE;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANIMALS; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; MICE; MOUTH MUCOSA; RHINITIS, ALLERGIC, SEASONAL;

EID: 34047209797     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2007.02709.x     Document Type: Editorial

References (34)

1. Herz U, Renz H, Wiedermann U. Animal models of type I allergy using recombinant allergens. Methods 2004; 32:271-80.
2. Bousquet J. Sublingual immunotherapy: from proven prevention to putative rapid relief of allergic symptoms. Allergy 2005; 60:1-3.
3. Passalacqua G, Guerra L, Pasquali M, Lombardi C, Canonica GW. Efficacy and safety of sublingual immunotherapy. Ann Allergy Asthma Immunol 2004; 93:3-12; quiz-3, 103.
4. Canonica GW, Passalacqua G. Noninjection routes for immunotherapy. J Allergy Clin Immunol 2003; 111:437-48; quiz 49.
5. Moingeon P, Batard T, Fadel R, Frati F, Sieber J, Van Overtvelt L. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy 2006; 61:151-65.
6. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006; 61:185-90.
7. Marcucci F, Sensi L, Di Cara G, Incorvaia C, Frati F. Dose dependence of immunological response to sublingual immunotherapy. Allergy 2005; 60:952-6.
8. Bufe A, Ziegler-Kirbach E, Stoeckmann E et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy 2004; 59:498-504.
9. Brimnes J, Kildsgaard J, Jacobi H, Lund K. Sublingual immunotherapy reduces allergic symptoms in a mouse model of rhinitis. Clin Exp Allergy 2007; 37:488-97.
10. Winkler B, Baier K, Wagner S et al. Mucosal tolerance as therapy of type I allergy: intranasal application of recombinant Bet v 1, the major birch pollen allergen, leads to the suppression of allergic immune responses and airway inflammation in sensitized mice. Clin Exp Allergy 2002; 32:30-36.
11. Winkler B, Hufnagl K, Spittler A et al. The role of Foxp3+T cells in long-term efficacy of prophylactic and therapeutic mucosal tolerance induction in mice. Allergy 2006; 61:173-80.
12. Ciprandi G, Fenoglio D, Cirillo I et al. Induction of interleukin 10 by sublingual immunotherapy for house dust mites: a preliminary report. Ann Allergy Asthma Immunol 2005; 95:38-44.
13. Fenoglio D, Puppo F, Cirillo I et al. Sublingual specific immunotherapy reduces PBMC proliferations. Allerg Immunol (Paris) 2005; 37:147-51.
14. Pajno GB, Morabito L, Barberio G, Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000; 55:842-9.
15. Wiedermann U. Prophylaxis and therapy of allergy by mucosal tolerance induction with recombinant allergens or allergen constructs. Curr Drug Targets Inflamm Allergy 2005; 4:577-83.
16. Ciprandi G, Fenoglio D, Cirillo I, Milanese M, Minuti P. Sublingual immunotherapy and regulatory T cells. Allergy 2006; 61:511-3.
17. Jutel M, Akdis M, Budak F et al. IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003; 33:1205-14.
18. Winkler B, Bolwig C, Seppala U, Spangfort MD, Ebner C, Wiedermann U. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 2003; 110:376-85.
19. Strachan DP. Family size, infection and atopy: the first decade of the "hygiene hypothesis". Thorax 2000; 55 (Suppl. 1):S2-10.
20. Yazdanbakhsh M, Kremsner PG, van Ree R. Allergy, parasites, and the hygiene hypothesis. Science 2002; 296:490-4.
21. Schaub B, Lauener R, von Mutius E. The many faces of the hygiene hypothesis. J Allergy Clin Immunol 2006; 117:969-77; quiz 78.
22. Bjorksten B, Naaber P, Sepp E, Mikelsaar M. The intestinal microflora in allergic Estonian and Swedish 2-year-old children. Clin Exp Allergy 1999; 29:342-6.
23. Kalliomaki M, Kirjavainen P, Eerola E, Kero P, Salminen S, Isolauri E. Distinct patterns of neonatal gut microflora in infants in whom atopy was and was not developing. J Allergy Clin Immunol 2001; 107:129-34.
24. Boyle RJ, Tang ML. The role of probiotics in the management of allergic disease. Clin Exp Allergy 2006; 36:568-76.
25. Kalliomaki M, Salminen S, Arvilommi H, Kero P, Koskinen P, Isolauri E. Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. Lancet 2001; 357:1076-9.
26. Taylor AL, Dunstan JA, Prescott SL. Probiotic supplementation for the first 6 months of life fails to reduce the risk of atopic dermatitis and increases the risk of allergen sensitization in high-risk children: a randomized controlled trial. J Allergy Clin Immunol 2007; 119:184-91.
27. Weizman Z, Asli G, Alsheikh A. Effect of a probiotic infant formula on infections in child care centers: comparison of two probiotic agents. Pediatrics 2005; 115:5-9.
28. Feleszko W, Jaworska J, Rha R-D et al. Probiotic-induced suppression of allergic sensitization and airway inflammation is associated with an increase of T regulatory-dependent mechanisms in a murine model of asthma. Clin Exp Allergy 2007; 37:498-505.
29. Repa A, Grangette C, Daniel C et al. Mucosal co-application of lactic acid bacteria and allergen induces counter-regulatory immune responses in a murine model of birch pollen allergy. Vaccine 2003; 22:87-95.
30. Daniel C, Repa A, Wild C et al. Modulation of allergic immune responses by mucosal application of recombinant lactic acid bacteria producing the major birch pollen allergen Bet v 1. Allergy 2006; 61:812-9.
31. Gerhold K, Avagyan A, Seib C et al. Prenatal initiation of endotoxin airway exposure prevents subsequent allergen-induced sensitization and airway inflammation in mice. J Allergy Clin Immunol 2006; 118:666-73.
32. Rautava S, Kalliomaki M, Isolauri E. Probiotics during pregnancy and breast-feeding might confer immunomodulatory protection against atopic disease in the infant. J Allergy Clin Immunol 2002; 109:119-21.
33. Pochard P, Gosset P, Grangette C et al. Lactic acid bacteria inhibit TH2 cytokine production by mononuclear cells from allergic patients. J Allergy Clin Immunol 2002; 110:617-23.
34. Smits HH, Engering A, van der Kleij D et al. Selective probiotic bacteria induce IL-10-producing regulatory T cells in vitro by modulating dendritic cell function through dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin. J Allergy Clin Immunol 2005; 115:1260-7.